Compare VOXR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOXR | FULC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.1M | 281.1M |
| IPO Year | 2022 | 2019 |
| Metric | VOXR | FULC |
|---|---|---|
| Price | $4.21 | $3.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 5 |
| Target Price | ★ $7.67 | $3.67 |
| AVG Volume (30 Days) | 526.9K | ★ 1.2M |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.99 | $2.83 |
| 52 Week High | $6.70 | $15.74 |
| Indicator | VOXR | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 53.24 |
| Support Level | $4.13 | $3.75 |
| Resistance Level | $5.16 | $3.81 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 10.16 | 71.88 |
Vox Royalty Corp is a returns-focused mining royalty and streaming company. It holds a diversified portfolio of several royalties and streams, including producing and development stage assets, with primary exposure to gold and select industrial metals across top-tier mining jurisdictions. Vox is organized into two operating segments, consisting of acquiring and managing royalty interests; and acquiring and managing streams and other interests. Maximum revenue is generated from its Royalty Interests segment. The majority of the company's portfolio of royalty, streams, and other interests by asset count is located in Australia, Canada, and the United States, of which the maximum revenue is derived from its assets in Australia.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.